logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 19 of 19 Items
Showing 1 - 19 of 19 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

The effectiveness and safety of bedaquiline, pretomanid, and linezolid (BPaL)-based regimens for rifampicin-resistant tuberculosis in non-trial settings - A prospective cohort study in Belarus and Uzbekistan

Sinha A, Klebe R, Rekart ML, Alvarez JL, Skrahina A,  et al.
2025-02-18 • Clinical Infectious Diseases
2025-02-18 • Clinical Infectious Diseases

BACKGROUND

Only 63% of patients initiating multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment in 2020 were treated successfully. 24-Wee...

Journal Article
|
Research

Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis

Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R,  et al.
2025-02-01 • Lancet Child and Adolescent Health
2025-02-01 • Lancet Child and Adolescent Health

BACKGROUND

There are few data on the treatment of children and adolescents with multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis, especially ...

Journal Article
|
Research

Supporting multidrug-resistant or rifampicin-resistant TB treatment adherence in people with harmful use of alcohol through person-centred care

Harrison RE, Shyleika V, Vishneuski R, Leonovich O, Vetushko D,  et al.
2024-11-06 • Oxford Medical Journal
2024-11-06 • Oxford Medical Journal

BACKGROUND

TB is concentrated in populations with complex health and social issues, including alcohol use disorders (AUD). We describe treatment adherence and o...

Journal Article
|
Review

Humanising and optimising HIV health care for refugees and asylum seekers

Cortes CP, Sued O, Wong WCW, Borquez A, Ssonko C,  et al.
2024-11-01 • Lancet HIV
2024-11-01 • Lancet HIV
Journal Article
|
Research

Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan

Moe S, Azamat I, Allamuratova S, Oluya M, Khristusev A,  et al.
2024-09-01 • IJTLD OPEN
2024-09-01 • IJTLD OPEN

BACKGROUND

Dru...

Journal Article
|
Research

Yield of TB screening in prisons in Tajikistan

Moe S, Asozoda M, Aung A, Dusmatova Z, Akintore F,  et al.
2024-08-01 • IJTLD OPEN
2024-08-01 • IJTLD OPEN

BACKGROUND

The rate of TB in prison institutions is estimated to be 23 times higher than in the general population. Limited documentation exists regarding TB screening in Tajiki...

Journal Article
|
Research

A 10-year review of isoniazid-resistant TB management in Uzbekistan 2009-2020

Rekart M, Thit P, Oluya M, Moe S, Hasan T,  et al.
2024-07-01 • IJTLD OPEN
2024-07-01 • IJTLD OPEN

Background

Isoniazid (INH, H) resistance is the most common drug-resistant TB pattern, with treatment success rates lower than those in drug-susceptible TB. The...

Journal Article
|
Research

Household drug-resistant TB contact tracing in Tajikistan

Rekart ML, Aung A, Cullip T, Mulanda WK, Mun L,  et al.
2023-10-01 • International Journal of Tuberculosis and Lung Disease
2023-10-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
Tajikistan has a high burden of rifampicin-resistant TB (RR-TB), with 2,700 new cases estimated for 2021 (28/100,000 population). TB is spread among household members thro...
Conference Material
|
Slide Presentation

Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus

Yatskevich N, Hurevich H, Solodovnikova V, Garsevanidze E, Lachenal N,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
Conference Material
|
Abstract

Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus

Yatskevich N, Hurevich H, Solodovnikova V, Garsevanidze E, Lachenal N,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
INTRODUCTION
The total duration of treatment for rifampicin-resistant tuberculosis (RR-TB) in Belarus prior to December 2022 was 18-20 months. The efficacy of treatment with such reg...
Journal Article
|
Research

Primary bedaquiline resistance in Karakalpakstan, Uzbekistan

Moe S, Rekart ML, Hernandez D, Sholpan A, Ismailov A,  et al.
2023-05-01 • International Journal of Tuberculosis and Lung Disease
2023-05-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND:
Bedaquiline (BDQ) is widely used in the treatment of rifampicin-resistant TB (RR-TB). However, resistance to BDQ is now emerging. There are no standardised regimens for ...
Journal Article
|
Research

Detection of Mycobacterium tuberculosis complex using the Xpert MTB/RIF Ultra assay on the stool of pediatric patients in Dushanbe, Tajikistan

Rekart ML, Mun L, Aung A, Gomez D, Mulanda WK,  et al.
2023-01-09 • Microbiology Spectrum
2023-01-09 • Microbiology Spectrum
We report the findings of a prospective laboratory diagnostic accuracy study to evaluate the sensitivity, specificity, and predictive values of the Xpert MTB/RIF Ultra assay for Mycobact...
Journal Article
|
Letter

Family directly observed therapy for children with drug-resistant TB

Rekart ML, Morshed T, Mulanda WK, Klieascikova J, Sitali N,  et al.
2022-08-01 • International Journal of Tuberculosis and Lung Disease
2022-08-01 • International Journal of Tuberculosis and Lung Disease
Protocol
|
Research Protocol

Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy

Sweeney S, Gomez G, Kitson N, Sinha A, Yatskevich N,  et al.
2020-10-10 • BMJ Open
2020-10-10 • BMJ Open
INTRODUCTION
Current treatment regimens for multidrug-resistant tuberculosis (MDR-TB) are long, poorly tolerated and have poor outcomes. Furthermore, the costs of treating MDR-TB are...
Conference Material
|
Poster

Detection of Mycobacterium tuberculosis complex in the stool of pediatric patients using the Xpert MTB/Rif Ultra assay

Mun L, Gomez D, Sitali N, Rajabzoda A, Azamova S,  et al.
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022
Conference Material
|
Poster

Patient and carer engagement in research agenda setting

Abramenko K, Shchenina K, Stringer B, Koerner L, Tan C,  et al.
2021-05-18 • MSF Scientific Days International 2021: Research
2021-05-18 • MSF Scientific Days International 2021: Research
Conference Material
|
Video

Community-centred programming - panel discussion

Ellman T, Ali Z, Raghaven V, Sadique S, Singh JA,  et al.
2021-05-18 • MSF Scientific Days International 2021: Research
2021-05-18 • MSF Scientific Days International 2021: Research
Conference Material
|
Poster

A common agenda: experiences of involving patients and carers in setting research agendas for tuberculosis care

Shchenina K, Stringer B, Koerner L, Tan C, Vishneuski R,  et al.
2021-05-18 • MSF Scientific Days International 2021: Research
2021-05-18 • MSF Scientific Days International 2021: Research
Journal Article
|
Research

Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan

Nair P, Hasan T, Zaw KK, Allamuratova S, Ismailov A,  et al.
2022-07-01 • International Journal of Tuberculosis and Lung Disease
2022-07-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The WHO recommends the use of bedaquiline (BDQ) in longer, as well as shorter, multidrug-resistant TB (MDR-TB) treatment regimens. However, resistance to this new drug is ...